<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18962">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860039</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PED 1647</org_study_id>
    <secondary_id>NCI-2016-01090</secondary_id>
    <nct_id>NCT02860039</nct_id>
  </id_info>
  <brief_title>High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant</brief_title>
  <official_title>Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II randomized trial studies how well high dose flu vaccine works in treating
      children who have undergone done stem cell transplant. Higher dose flu vaccine may build a
      better immune response and may provide better protection against the flu than the standard
      vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether high-dose trivalent inactivated influenza vaccine (HD-TIV) compared
      with standard dose quadrivalent inactivated influenza vaccine (QIV) will increase the
      probability of achieving a &gt;= 4-fold rise in hemagglutination-inhibition (HAI) titers, &gt;=
      1:40 HAI titer, or higher geometric mean titer (GMT) to influenza A antigens in pediatric
      hematopoietic stem cell transplant (HSCT) recipients.

      SECONDARY OBJECTIVES:

      I. To determine whether HD-TIV compared with standard dose QIV will increase the probability
      of achieving a &gt;= 4-fold rise in HAI titers, &gt;= 1:40 HAI titer, or higher GMT titers to
      influenza B antigens in pediatric HSCT recipients.

      II. To determine the frequency and severity of solicited local injection site adverse events
      (e.g. pain/ tenderness, redness, and swelling at injection site) with HD-TIV compared to
      standard QIV in pediatric HSCT recipients.

      III. To determine the frequency and severity of solicited systemic adverse events (e.g.
      fevers, headache, fatigue/malaise, nausea, body ache/myalgia, general activity level, and
      vomiting) with HD-TIV compared to standard dose QIV in pediatric HSCT recipients.

      IV. To define the relationship between HAI titers, in vivo T and B cell phenotype, and in
      vitro influenza-specific T and B cell response in pediatric HSCT recipients receiving either
      HD-TIV or standard dose QIV.

      V. To correlate HAI responses to microneutralization responses.

      VI. To compare the persistent HAI and microneutralization (MN) titers for all four antigen
      seven months after the last vaccine dose to assess for persistence of antibody titers.

      VII. To compare influenza detection by PCR during influenza season in pediatric HSCT
      recipients receiving either HD-TIV or standard dose QIV.

      OUTLINE: Patients are randomized to 1 of 2 treatment groups.

      GROUP I (Experimental): Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.

      GROUP II (Standard): Patients receive standard dose QIV IM on day 0 and day 28.

      After completion of study treatment, patients are followed up at 28-42 days, and at 7
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity as measured by the number of subjects who achieve a 4-fold (or greater) rise in post-vaccination HAI titers</measure>
    <time_frame>Baseline up to 7 months after the second vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of solicited local injection site adverse events</measure>
    <time_frame>Up to 7 days following each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T and B cell phenotype assessed by mass cytometry</measure>
    <time_frame>Up to 7 months after second vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T and B cell response assessed by mass cytometry and in-vitro functionality assays</measure>
    <time_frame>Up to 7 months after second vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of individuals in each group who test positive for influenza</measure>
    <time_frame>During the influenza season, up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Malignant Neoplasm</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1 - High Dose HD-TIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Standard Dose QIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard dose QIV IM on day 0 and day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Influenza Vaccine</intervention_name>
    <description>High dose Trivalent Influenza Vaccine given intramuscular</description>
    <arm_group_label>Group 1 - High Dose HD-TIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Vaccine</intervention_name>
    <description>Standard dose Quadrivalent Influenza Vaccine given intramuscular</description>
    <arm_group_label>Group 2 - Standard Dose QIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group 1 - High Dose HD-TIV</arm_group_label>
    <arm_group_label>Group 2 - Standard Dose QIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic HSCT recipients who are 3-35 months post-transplant

          -  Available for duration of study

          -  If patients are on immunosuppressive therapy for treatment of graft versus host
             disease (GVHD), then only those on stable doses for at least 4 weeks (or on tapering
             doses) will be eligible

          -  Parent/legal guardian willing and capable of signing written informed consent

          -  Parent/legal guardian expected to be available for entire study

          -  Parent/legal guardian can be reached by telephone or email

          -  Must have a platelet count of ≥30,000 to receive the immunizations. Patients
             requiring platelet transfusions are eligible to enroll and must have a platelet count
             ≥30,000 within 72 hours prior to their immunization. For subjects &lt;12 months
             post-transplant, if a platelet count of ≥75,000 is documented without transfusion
             support within 14 days of the immunization, then an additional platelet count does
             not need to be repeated prior to immunization. For subjects 12-35 months
             post-transplant, if a platelet count of ≥75,000 is documented without transfusion
             support within 90 days of the immunization, then an additional platelet count does
             not need to be repeated prior to immunization.

        Exclusion Criteria:

          -  History of hypersensitivity to previous influenza vaccination or severe or moderate
             hypersensitivity to eggs/egg protein

          -  History of Guillain-Barre syndrome

          -  Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed
             chimerisms is permitted)

          -  History of receiving 2016-2017 influenza vaccine

          -  Pregnant female

          -  History of proven influenza disease after September 1, 2016

          -  Non-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant
             (SCT) recipients

          -  Platelet count less than 30,000 cells/uL

          -  History of known active infection with human immunodeficiency virus (HIV), hepatitis
             B or hepatitis C

          -  History of known latex hypersensitivity

          -  Subjects who have received stem cell boost or delayed donor lymphocyte infusion
             within 90 days of enrollment, including day of enrollment

          -  Receipt of intravenous immunoglobulin therapy (IVIG) &lt; 27 days prior to vaccination

          -  C34 selection or other ex-vivo T-cell depletion, post-transplant cytoxan for
             aploidentical transplants is allowable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Halasa, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Reporting Program</last_name>
    <phone>800-811-8480</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Lu</last_name>
      <phone>415-476-3833</phone>
    </contact>
    <investigator>
      <last_name>Rachel Wattier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nowak</last_name>
      <phone>816-234-3352</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Blum</last_name>
      <phone>513-803-7939</phone>
    </contact>
    <investigator>
      <last_name>Lara Danziger-Isakov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Ott-Napier</last_name>
      <phone>614-722-6313</phone>
    </contact>
    <investigator>
      <last_name>Monica Ardura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn O'Connor</last_name>
      <phone>267-426-5292</phone>
    </contact>
    <investigator>
      <last_name>Susan Coffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Allison</last_name>
      <phone>901-595-3252</phone>
    </contact>
    <investigator>
      <last_name>Gabriela Maron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Natasha Halasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Williams</last_name>
      <phone>832-824-1580</phone>
    </contact>
    <investigator>
      <last_name>Flor Munoz-Rivas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Kinnunen</last_name>
      <phone>206-884-2205</phone>
    </contact>
    <investigator>
      <last_name>Janet Englund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 5, 2017</lastchanged_date>
  <firstreceived_date>August 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Natasha Halasa, MD</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
